GILD: EU Approves Trodelvy
GILD's Trodelvy approved by European Commission as first-line treatment for metastatic triple-negative breast cancer patients
GILD European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors